Loading...
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall surv...
Na minha lista:
| Udgivet i: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5970460/ https://ncbi.nlm.nih.gov/pubmed/29801474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4453-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|